Beizray is a drug owned by Zhuhai Beihai Biotech Co Ltd. It is protected by 3 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 16, 2036. Details of Beizray's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11419842 | Neutral pH compositions of Docetaxel and human serum albumin |
May, 2036
(11 years from now) | Active |
| US12090134 | Neutral pH compositions of docetaxel and human serum albumin |
May, 2036
(11 years from now) | Active |
| US12090135 | Neutral pH compositions of docetaxel and human serum albumin |
May, 2036
(11 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Beizray is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Beizray's family patents as well as insights into ongoing legal events on those patents.
Beizray's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Beizray's generic launch date based on the expiry of its last outstanding patent is estimated to be May 16, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Beizray Generic API suppliers:
Docetaxel is the generic name for the brand Beizray. 15 different companies have already filed for the generic of Beizray, with Hengrui Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Beizray's generic
Alternative Brands for Beizray
There are several other brand drugs using the same active ingredient (Docetaxel) as Beizray. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Docetaxel, Beizray's active ingredient. Check the complete list of approved generic manufacturers for Beizray
About Beizray
Beizray is a drug owned by Zhuhai Beihai Biotech Co Ltd. Beizray uses Docetaxel as an active ingredient. Beizray was launched by Zhuhai in 2024.
Approval Date:
Beizray was approved by FDA for market use on 23 October, 2024.
Active Ingredient:
Beizray uses Docetaxel as the active ingredient. Check out other Drugs and Companies using Docetaxel ingredient
Dosage:
Beizray is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 80MG/4ML (20MG/ML) | SOLUTION | Prescription | INTRAVENOUS |